Amendments to the Claims:

1. (Original) A process for preparing crystalline particles of substance which comprises mixing in a continuous flow cell in the presence of ultrasonic radiation a flowing solution of the substance in a liquid solvent with a flowing liquid anti-solvent for said substance, and collecting the resultant crystalline particles generated, characterised in that the solution and anti-solvent are delivered into the continuous flow cell in parallel contacting streams.

2. (Cancelled)

3. (Original) A process according to claim 1 wherein the liquid anti-solvent is miscible with the liquid solvent.

4-15. (Cancelled)

16. (Previously presented) A process for preparing crystalline particles of substance which comprises mixing in a continuous flow cell in the presence of ultrasonic radiation a flowing solution of the substance in a liquid solvent with a flowing liquid anti-solvent for said substance, and collecting the resultant crystalline particles generated, characterised in that the solution and anti-solvent are delivered into the continuous flow cell in parallel contacting streams using an apparatus according to claim 2 which comprises:
(i) delivering the contents of the first and second reservoirs to the mixing chamber via the first and second inlet ports respectively at independent controlled flow rate;
(ii) supplying ultrasonic radiation to the vicinity of the inlet ports; and
(iii) collecting the crystalline particles suspended in the liquid discharged from the mixing chamber at the outlet port.

17. (Original) A process according to claim 16 wherein the substance is a pharmaceutical or carrier substance suitable for inhalation therapy.

18. (Original) A process according to claim 17 wherein the substance is fluticasone, beclomethasone, salmeterol, salbutamol or an ester, salt or solvate thereof.

19. (Original) A process according to claim 17 wherein the substance is lactose.

20. (Original) A process according to claim 18 wherein the substance is fluticasone propionate.

21. (Original) A process according to claim 18 wherein the substance is salmeterol xinafoate.

22. (Previously presented) A process according to claim 1 wherein the substance is a mixture.

23. (Original) A process according to claim 22 wherein the substance is a mixture of fluticasone propionate and salmeterol xinafoate.

24. (Previously presented) A process according to claim 20 wherein the solvent is acetone and the anti-solvent is water.

25. (Original) A process according to claim 21 wherein the solvent is methanol and the anti-solvent is water.

26. (Original) A process according to claim 16 wherein the substance is naratriptan hydrochloride.

27-28. (Cancelled)